Home   Business   Article

Abcam expects double digit revenue growth

By Paul Brackley

Abcam delivered double digit revenue growth for the second half of 2018, according to an unaudited trading update issued today (Tuesday).

Alan Hirzil, Abcam. (6394603)
Alan Hirzil, Abcam. (6394603)

The life science research tools company, which is building its new HQ on Cambridge Biomedical Campus, says it is gaining market share in recombinant antibodies and immunoassays, while expanding in China.

It expects total revenue growth for the six months to the end of 2018 to be 11 per cent on a reported basis and 10 per cent on a constant currency basis, which eliminates exchange rate fluctuations.

Alan Hirzel, CEO of Abcam, whose presentation to the 37th Annual JP Morgan Healthcare Conference on Wednesday (January 9, 2019) will be available as a webcast on the company’s site, said: “Global demand is strong for precision life science tools and Abcam has once again gained market share in these growing markets. Our business is on track to achieve double-digit growth for the year.

Abcam at CBC. (6394608)
Abcam at CBC. (6394608)

“During the half we have continued to focus on improving our service for customers. We have further developed our product portfolio and we have continued to enhance our organisational capabilities to support our ambition of becoming the most influential company for life scientists, supporting research, diagnostic and therapeutic discovery.”

The company said its performance was the “result of the multiyear invest-to-grow strategy that has guided the business over the last five years”.

Its recombinant antibody revenues grew 20 per cent, while immunoassays grew 27 per cent. Catalogue revenue grew by more than 10 per cent on a constant currency basis.

Abcam at CBC. (6394611)
Abcam at CBC. (6394611)

Abcam said it expects a gross margin “modestly ahead of last year” and had “begun implementing contingency plans ahead of a potential ‘no-deal’ Brexit in order to minimise the risk of disruption to customers”.


Iliffe Media does not moderate comments. Please click here for our house rules.

People who post abusive comments about other users or those featured in articles will be banned.

Thank you. Your comment has been received and will appear on the site shortly.


Terms of Comments

We do not actively moderate, monitor or edit contributions to the reader comments but we may intervene and take such action as we think necessary, please click here for our house rules.

If you have any concerns over the contents on our site, please either register those concerns using the report abuse button, contact us here.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More